Effect of a new antithrombotic agent at microvenous anastomotic sites.
In the search for a suitable agent to prevent thrombosis at microvenous anastomotic sites, a double-blind sequential trial was performed to evaluate the effect of a new potent antithrombotic agent, 6-methyl-1,2,3,5-tetrahydroimidazo [2, 1-b] quinazolin-2-one hydrochloride monohydrate (BL3459). Rabbit neck veins 1.5 mm in diameter, were chosen for study and were anastomosed with Nakayama ring pins. In a comparison with heparin, the results show a highly statistical diminution in thrombosis rates when using BL3459. It would appear that this new compound would substantially improve tissue survival if it were adopted for use clinically for grafting autologous tissue that is based on an anastomosed microvascular pedicle. It could also prove to be clinically useful to treat a variety of problems requiring an antithrombotic agent.
D000818:Animals; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use; D007093:Imidazoles / Q000627:therapeutic use; D008297:Male; D008866:Microsurgery; D011799:Quinazolines / Q000627:therapeutic use*; D011817:Rabbits; D013927:Thrombosis / Q000517:prevention & control; D014680:Veins / Q000601:surgery*
D005343:Fibrinolytic Agents; D007093:Imidazoles; D011799:Quinazolines; D006493:Heparin